BUND FINANCE › Stocks › BSX
Boston Scientific Corporation (BSX)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is -0.57% below its 50-day average.
- It is -18.66% below its 200-day average (long-term downtrend).
- It sits at 7% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$11.9B | US$12.7B | US$14.2B | US$16.7B | US$20.1B |
| Net income | US$1.0B | US$698.0M | US$1.6B | US$1.9B | US$2.9B |
| EPS (diluted) | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 |
| Gross margin | 68.8% | 60.8% | 62.0% | 61.3% | 69.0% |
| Operating margin | 10.1% | 14.4% | 15.3% | 15.7% | 19.8% |
| Net margin | 8.8% | 5.5% | 11.2% | 11.1% | 14.4% |
| Free cash flow | US$1.3B | US$938.0M | US$1.8B | US$2.6B | US$3.7B |
| Total debt | US$9.5B | US$9.3B | US$9.5B | US$11.1B | US$12.4B |
| Cash | US$1.9B | US$928.0M | US$865.0M | US$414.0M | US$2.0B |
Compound annual growth: revenue 14.0% · net income 29.1% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 18.5x | 67.5x | 27.1x |
| EV / EBITDA | 13.8x | 29.4x | 16.5x |
| Operating margin | 21.1% | — | 3.6% |
| Net margin | 16.6% | — | -0.0% |
| Debt / equity | 0.76 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Boston Scientific Corporation
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, …
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice